FOLH1 and neoplasm: The 2 h uptake rate of the PMSA tetramer DOTA-(2P-PEG4)2 reached 27.57 ± 7.07%, and both DOTA-(2P-PEG4)2 and DOTA-(2P-PEG4) had higher cellular uptake rates than DOTA-(1P-PEG4), proving that the multimer PSMA could benefit the binding between ligands and tumor cells.